bioMérieux: FilmArray growth prospects intact, it is all about value added

The sustainability of FilmArray growth prospects was the centre of interest during the group meeting with Alexandre Mérieux, bioMérieux’s CEO. This seems intact as highlighted by 1/ clinical value-added of FilmArray (depicted in several 2016 ASM’s abstracts) which is increasingly echoed by clinicians, 2/ a good performance by the respiratory panel accounting for 80% of FilmArray sales and 3/ ramp-up of other panels both in the US and in Europe (Japan as free upside). The tougher US reimbursement framework does not impact BIM.

For more information please contact marketing@bryangarnier.com